Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE).

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Designing Consent Processes for Research With Older Adults Who May Lack Decisional Capacity: A Guide for Investigators.

Journal of the American Geriatrics Society·2026
Same author

Four Common Beliefs About Patient Memory Evaluations: Who Has Them and What Modifies Them?

American journal of Alzheimer's disease and other dementias·2026
Same author

Expert consensus on communicating tau PET results to persons living with MCI or dementia: Findings from a modified Delphi study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress.

JAMA network open·2026
Same author

Effects of caregiving experience on expectations of becoming an Alzheimer's disease caregiver in the future.

The journals of gerontology. Series B, Psychological sciences and social sciences·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Abigail Perelman1, Megan Zhang2, Cameron Coykendall1

  • 1University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

血化tau181 (p-tau181) 测试为阿尔茨海默病 (AD) 诊断提供了宝贵的见解. 虽然信息丰富,但结果可能会给患者和护理伙伴带来痛苦,需要支持.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物研究 生物标志物研究
  • 临床诊断 临床诊断 临床诊断

背景情况:

  • 早期阿尔茨海默病 (AD) 诊断对于及时的护理和规划至关重要.
  • 基于等离子体的生物标志物,如化tau181 (p-tau181),正在成为早期AD检测的可访问工具.
  • p-tau181可以将AD与其他疾病区分开来,并预测认知衰退.

研究的目的:

  • 评估血p-tau181测试对患者及其护理伙伴在记忆诊所环境中的临床影响.
  • 评估p-tau181测试结果的心理影响和实用性.

主要方法:

  • 患有轻度认知障碍或痴呆症的患者接受了血p-tau181测试.
  • 患者和研究伙伴 (SPs) 在结果披露之前和之后完成了焦虑和抑郁症尺度.
  • 调查评估了在短期和中期随访中测试结果的理解和有用性.

主要成果:

  • 研究伙伴 (SPs) 在披露后显著增加了焦虑 (p=0.003).
  • 没有观察到患者焦虑或抑郁的显著变化.
  • 大多数患者和医生发现p-tau181测试结果信息丰富且有用.

结论:

  • 像p-tau181这样的等离子AD生物标志物提供了有价值的诊断信息.
  • 测试结果可能会引起心理困扰,这凸显了需要适当的支持系统的需要.
  • 在现实环境中进一步评估对于血AD生物标志物的广泛临床采用至关重要.